News
July 16, 2008
Accuri Cytometers Raises $13 Million in Venture Capital, Plans to Double in Size
Concentrate, 7/16/2008
As if the term "T-cell count" isn't confusing enough try figuring out "flow cytometer system".
But the people behind Ann Arbor's Accuri Cytometers are experts in both, especially the latter. The 3-year-old biotechnology company specializes in making the cytomer systems that measure things like T-cell counts, which is an instrumental tool in treating diseases like AIDS and cancer.
And since cures for either seem on the distant horizon, the biotech firm has plenty of room to grow. Accuri has gone from its two initial founders to 35 people today. It has three open positions ready to be filled and expects to double in size within the next 12 to 18 months. That's on the heels of raising $13 million in financing.
"We've been busy and we're hiring more," says Jennifer Baird, president and CEO of Accuri Cytometers.
Although not all of those jobs will be based in Ann Arbor, the University of Michigan spin-off plans to dip into the deep pool of local talent to fill many of those new jobs. It plans to do so in Ann Arbor where it has received more than a warm welcome.
"We've gotten great support from the state of Michigan and the University of Michigan," Baird says.
Source: Jennifer Baird, president and CEO of Accuri Cytometers
Writer: Jon Zemke
|
